[1]李子文 蔺雅娟 樊瑞 夏云龙 杨晓蕾.中青年冠心病患者中血清尿酸水平与冠脉狭窄程度的关系：一项单中心回顾性研究[J].心血管病学进展,2021,(12):1136-1141,1153.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.019]
　LI Ziwen,LIN Yajuan,FAN Rui,et al.Relationship Between Serum Uric Acid Level and Coronary Artery Stenosis in Patients with Coronary Heart Disease:a Single-Center Retrospective Study[J].Advances in Cardiovascular Diseases,2021,(12):1136-1141,1153.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.019]
点击复制

中青年冠心病患者中血清尿酸水平与冠脉狭窄程度的关系：一项单中心回顾性研究()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年12期
页码:
1136-1141,1153
栏目:
论著
出版日期:
2021-12-25

文章信息/Info

Title:
Relationship Between Serum Uric Acid Level and Coronary Artery Stenosis in Patients with Coronary Heart Disease:a Single-Center Retrospective Study
作者:
李子文 蔺雅娟 樊瑞 夏云龙 杨晓蕾
(大连医科大学第一附属医院 心血管病医院 辽宁 大连 116011)
Author(s):
LI Ziwen; LIN Yajuan; FAN Rui; XIA Yunlong; YANG Xiaolei
(The First Affiliated Hospital of Dalian Medical University,Dalian 116011,Liaoning,China)
关键词:
尿酸; 冠心病; 年龄
Keywords:
Uric acid; Coronary heart disease; Age
DOI:
10.16806/j.cnki.issn.1004-3934.2021.12.019
摘要:
目的 通过回顾性研究分析中青年冠心病患者中影响冠状动脉血管狭窄程度临床因素，探讨中青年冠心病患者入院时血清尿酸（SUA）水平与冠状动脉血管狭窄程度之间的流行病学关系。方法 连续入选2010年1月至2020年6月期间于大连医科大学心血管病医院就诊的中青年冠心病患者，年龄20～65岁，共计8 644人，排除无SUA值、高血压、糖尿病、痛风、肿瘤、肾功能不全、心力衰竭等影响SUA水平的患者，最终纳入中青年冠心病患者共3 957例。根据冠状动脉造影结果分为重度狭窄（任何一支冠状动脉狭窄程度≥75%）（n=1 016）和轻中度狭窄组（n=2 941）。比较两组患者的临床特点及冠状动脉造影治疗结果，分析SUA水平是否对冠状动脉血管狭窄程度产生影响。结果 （1）基线资料显示冠状动脉血管重度狭窄组患者的SUA水平为360（307~423） μmol/L，显著高于轻中度狭窄组335（279~399） μmol/L（P<0.001）；且spearman相关分析显示，SUA水平与冠状动脉血管狭窄程度之间呈正相关（R=0.129，P<0.001）；应用二元logistic回归分析，以SUA Q1分层为参考，随着SUA水平的升高冠状动脉血管重度狭窄的风险升高，Q3、Q4的校正OR值分别为1.267与1.372倍。（2）ROC曲线示20～35岁冠心病人群中，SUA对重度冠状动脉血管狭窄具有较高的预测价值（AUC=0.741，灵敏度75.5%，特异度65.5%）。且SUA＞422.5 μmol/L比SUA≤422.5 μmol/L患者重度狭窄的患病率高（44.2% vs 11.9%，P<0.001）。（3）对20~35岁人群进行多因素二元logistic回归分析显示SUA＞422.5 μmol/L患者冠状动脉血管重度狭窄的风险是SUA≤422.5 μmol/L者的5.8倍（OR=5.8，95%CI 2.020 ~16.653，P=0.001）结论 SUA水平与中青年冠心病患者冠状动脉狭窄程度呈显著相关性，患者SUA水平越高，冠状动脉血管重度狭窄的风险越大；在20~35岁冠心病人群中，SUA可能对冠心病患者冠状动脉狭窄程度具有较高的预测价值。
Abstract:
Objective Through a large sample retrospective study,to examine the clinical factors influencing the extent of coronary vascular stenosis in young and middle-aged patients with coronary heart disease,and to investigate the effect of serum uric acid(SUA) level on the extent of coronary vascular stenosis. Methods Totally 8 644 coronary heart disease patients who were admitted at the First Affiliated Hospital of Dalian Medical University from January 2010 to June 2020 aged between 20 and 65 years old were included. After excluding patients without SUA value ,and patients with hypertension,diabetes,gout,tumor,and renal function deficiency,and heart failure,finally 3 957 young and middle-aged patients were included. According to coronary angiography,they were divided into severe stenosis group(n=1 016) and mild-to-moderate stenosis group(n=2 941). The clinical characteristics and the results of coronary angiography were compared between the two groups,and whether the SUA level had an effect on the extent of coronary artery stenosis was analyzed. Results (1) The baseline data shows that the SUA level of patients with severe coronary artery stenosis group was 360 (307-423) μmol/L,which is significantly higher than that of the mild-to-moderate stenosis group 335(279~399) μmol/L (P<0.001); And Spearman correlation analysis shows that there is a positive correlation between SUA level and coronary artery stenosis ( R=0.129,P<0.001); binary logistic regression analysis shows,compared with the first quartile of SUA,as the level of SUA Increasing the risk of severe coronary artery stenosis is increased,and the adjusted OR values of Q3 ,and Q4 were 1.267 and 1.372,respectively. (2) ROC curve shows that in patients with coronary heart disease aged 20~35,SUA has a high predictive value for severe coronary artery stenosis ( AUC=0.741,sensitivity 75.5%,specificity 65.5%). And the prevalence of severe stenosis is higher in patients with SUA＞422.5 μmol/L than that with SUA≤422.5 μmol/L(44.2% vs 11.9%,P<0.001). (3) Multivariate logistic regression analysis of 20~35 years old patients shows that the risk of severe coronary artery stenosis in patients with SUA＞422.5 μmol/L was 5.8 times than those with SUA ≤422.5 μmol/L(OR=5.8,95%CI 2.020~16.653,P=0.001).Conclusions SUA levels are significantly correlated with the extent of coronary artery stenosis in young and middle-aged patients with coronary heart disease,and patients with higher SUA has higher risk association of severe coronary artery stenosis; among 20 to 35-year-old people with coronary heart disease,SUA may have a higher predictive value for the extent of coronary artery stenosis.

参考文献/References:

[1] Vaisi-Raygani A,Ghaneialvar H,Rahimi Z,et al. The angiotensin converting enzyme D allele is an independent risk factor for early onset coronary artery disease[J].Clin Biochem,2010,43(15):1189-1194.

[2] Hata J,Kiyohara Y.Epidemiology of stroke and coronary artery disease in Asia[J].Circ J,2013,77(8):1923-1932.

[3] Che J,Li G,Shao Y,et al. An analysis of the risk factors for premature coronary artery disease in young and middle-age Chinese patients with hypertension[J].Exp Clin Cardiol,2013,18(2):89-92.

[4] Kannel WB,Abbott RD.Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study[J].N Engl J Med,1984,311(18):1144-1147.

[5] Afifi M.Antecedant risk factors and their control in young patients with a first myocardial infarction[J].Singapore Med J,2006,47(6):554-555; author reply 555-556.

[6] Chouhan L,Hajar HA,Pomposiello JC.Comparison of thrombolytic therapy for acute myocardial infarction in patients aged < 35 and > 55 years[J].Am J Cardiol,1993,71(2):157-159.

[7] Hoit BD,Gilpin EA,Henning H,et al. Myocardial infarction in young patients:an analysis by age subsets[J].Circulation,1986,74(4):712-721.

[8] Zimmerman FH,Cameron A,Fisher LD,et al. Myocardial infarction in young adults: angiographic characterization,risk factors and prognosis (Coronary Artery Surgery Study Registry)[J].J Am Coll Cardiol,1995,26(3):654-661.

[9] de Becker B,Borghi C,Burnier M,et al.Uric acid and hypertension: a focused review and practical recommendations[J].J Hypertens,2019,37(5):878-883.

[10] Katsiki N,Papanas N,Fonseca VA,et al.Uric acid and diabetes:is there a link?[J]. Curr Pharm Des ,2013,19(27):4930-4937.

[11] Battelli MG,Bortolotti M,Polito L,et al.The role of xanthine oxidoreductase and uric acid in metabolic syndrome,Biochimica et biophysica acta[J]. Biochim Biophys Acta Mol Basis Dis,2018,1864(8):2557-2565.

[12] Zhao D,Liu J,Wang M,et al.Epidemiology of cardiovascular disease in China:current features and implications,Nature reviews[J]. Nat Rev Cardiol,2019,16(4):203-212.

[13] Duran M,Kalay N,Akpek M,et al.High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome[J].Angiology,2012,63(6):448-452.

[14] Fang J,Alderman MH.Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study,1971-1992. National Health and Nutrition Examination Survey[J].JAMA,2000,283(18):2404-2410.

[15] Li YH,Lin GM,Lin CL,et al.Relation of serum uric acid and body mass index to mortality in high-risk patients with established coronary artery disease:a report from the ET-CHD registry,1997-2006[J].J Cardiol,2013,62(6):354-360.

[16] Okura T,Higaki J,Kurata M,et al.Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study[J].Circ J,2009,73(5):885-891.

[17] Maynard C,Fisher LD,Passamani ER,et al.Blacks in the Coronary Artery Surgery Study: risk factors and coronary artery disease[J].Circulation,1986,74(1):64-71.

[18] Culleton BF,Larson MG,Kannel WB,et al. Serum uric acid and risk for cardiovascular disease and death:the Framingham Heart Study[J].Ann Intern Med,1999,131(1):7-13.

[19] Moriarity JT,Folsom AR,Iribarren C,et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study[J].Ann Epidemiol,2000,10(3):136-143.

[20] Wheeler JG,Juzwishin KD,Eiriksdottir G,et al.Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls:prospective study and meta-analysis[J].PLoS Med,2005,2(3):e76.

[21] King C,Lanaspa MA,Jensen T,et al.Uric acid as a cause of the metabolic syndrome[J].Contrib Nephrol,2018,192:88-102.

[22] Grossman C,Grossman E,Goldbourt U.Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality[J].PloS One,2019,14(8):e0220532.

[23] Meisinger C,Koenig W,Baumert J,et al. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population:the MONICA/KORA cohort study[J].Arterioscler T hromb V asc B iol,2008,28(6):1186-1192.

[24] Chen JH,Chuang SY,Chen HJ,et al. Serum uric acid level as an independent risk factor for all-cause,cardiovascular,and ischemic stroke mortality:a Chinese cohort study[J].Arthritis Rheum,2009,61(2):225-232.

[25] Kleber ME,Delgado G,Grammer TB,et al. Uric acid and cardiovascular events: a mendelian randomization study[J].J Am Soc Nephrol,2015,26(11):2831-2838.

[26] Sun Y,Zhang H,Tian W,et al. Association between serum uric acid levels and coronary artery disease in different age and gender: a cross-sectional study[J].Aging Clin E xp R es,2019,31(12):1783-1790.

[27] Dai XM,Wei L,Ma LL,et al. Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease[J].Clin Rheumatol,2015,34(9):1605-1611.

[28] Cheong E,Ryu S,Lee JY,et al. Association between serum uric acid and cardiovascular mortality and all-cause mortality:a cohort study[J].J H ypertens,2017,35(suppl 1):s3-s9.

[29] Lim SS,Yang YL,Chen SC,et al. Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention[J].Atherosclerosis,2020,297:40-46.

[30] Shi Y,Zhang X,Du J,et al. Elevated postoperative serum uric acid is associated with major adverse events following coronary artery bypass grafting[J].J C ard S urg,2020,35(10):2559-2566.

[31] Lin HC,Daimon M,Wang CH,et al. Allopurinol,benzbromarone and risk of coronary heart disease in gout patients:a population-based study [J]. Int J C ardiol,2017,233:85-90.

[32] Doehner W,Schoene N,Rauchhaus M,et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies[J]. Circulation,2002,105(22):2619-2624.

[33] Yang ZJ,Liu J,Ge JP,et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study[J]. Eur Heart J ,2012,33(2):213-220.

[34] Sharma M,Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors [J]. Vasc Health Risk Manag ,2005,1(3):217-225.

[35] Reibis R,Treszl A,Wegscheider K,et al. Disparity in risk factor pattern in premature versus late-onset coronary artery disease: a survey of 15,381 patients[J]. Vasc Health Risk Manag ,2012,8:473-481.

[36] Zand S,Shafiee A,Boroumand M,et al. Serum uric Acid is not an independent risk factor for premature coronary artery disease[J]. Cardiorenal Med ,2013,3(4):246-253.

[37] Tian TT,Li H,Chen SJ,et al. Serum uric acid as an independent risk factor for the presence and severity of early-onset coronary artery disease: a case-control study[J]. Dis Markers ,2018,2018:1236837.

[38] Biscaglia S,Ceconi C,Malagù M,et al. Uric acid and coronary artery disease:an elusive link deserving further attention[J]. Int J Cardiol,2016,213:28-32.

[39] Ruggiero C,Cherubini A,Ble A,et al. Uric acid and inflammatory markers[J].Eur H eart J,2006,27(10):1174-1181.

[40] Prasad M,Matteson EL,Herrmann J,et al. Uric acid is associated with inflammation,coronary microvascular dysfunction,and adverse outcomes in postmenopausal women[J]. Hypertension ,2017,69(2):236-242.

[41] Li H,Qian F,Liu H,et al. Elevated uric acid levels promote vascular smooth muscle cells (VSMC) proliferation via an nod-like receptor protein 3 (NLRP3)-inflammasome-dependent mechanism[J].Med S ci M onit,2019,25:8457-8464.

相似文献/References:

[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
　DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(12):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
　NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(12):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
　LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(12):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
　YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(12):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
　SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(12):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
　GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(12):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
　DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(12):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
　CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(12):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
　YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
　GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(12):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81900439/81970286）
通信作者：杨晓蕾，E-mail:yangxl1012@yeah.net?/div>
收稿日期：2021-06-07
更新日期/Last Update: 2022-01-07